The method of treating cancer of claim 10, wherein the cancer is characterized by constitutive activation of a mitogen-activated protein kinase-signaling pathway associated with one or more mutations in BRAF, KIT and/or RAS.ġ6. The method of treating cancer of claim 10, wherein the cancer is characterized by constitutive activation of a mitogen-activated protein kinase-signaling pathway.ġ5. The method of treating cancer of claim 10, wherein the WEE1 inhibitor is selected from the group consisting of: MK1775, a pharmaceutically acceptable salt, hydrate, amide or ester thereof and an siRNA directed to WEE1.ġ4. The method of treating cancer of claim 10, wherein the AKT inhibitor is selected from the group consisting of: AZD5363, GDC0068, a combination of AZD5363 and GDC0068, a pharmaceutically acceptable salt, hydrate, amide or ester of any thereof and an siRNA directed to AKT.ġ3.

The method of claim 10, wherein administration of the combination provides a synergistic effect.ġ2.

A method of treating cancer in a subject in need thereof, comprising: administering a combination of an AKT inhibitor and a WEE1 inhibitor as a combination formulation or separately.ġ1. The commercial package of claim 5, wherein the AKT inhibitor and the WEE1 inhibitor are provided as a single pharmaceutical formulation.ġ0. The commercial package of claim 5, wherein the WEE1 inhibitor is selected from the group consisting of: MK1775, a pharmaceutically acceptable salt, hydrate, amide or ester thereof, and an siRNA directed to WEE1.Ĩ.

The commercial package of claim 5, wherein the AKT inhibitor is selected from the group consisting of: AZD5363, GDC0068, a combination of AZD5363 and GDC0068, a pharmaceutically acceptable salt, hydrate, amide or ester of any thereof, and an siRNA directed to AKT.ħ. A commercial package comprising an AKT inhibitor and a WEE1 inhibitor.Ħ. The composition of claim 1, further comprising a pharmaceutically acceptable carrier.ĥ. The composition of claim 1, wherein the WEE1 inhibitor is selected from the group consisting of: MK1775, a pharmaceutically acceptable salt, hydrate, amide or ester thereof, and an siRNA directed to WEE1.Ĥ. The composition of claim 1, wherein the AKT inhibitor is selected from the group consisting of: AZD5363, GDC0068, a combination of AZD5363 and GDC0068, a pharmaceutically acceptable salt, hydrate, amide or ester of any thereof, and an siRNA directed to AKT.ģ. A composition comprising: an AKT inhibitor and a WEE1 inhibitor.Ģ.

Calcusyn Crack